Advanced kidney cancer (RCC) View all clinical trials KEYTRUDA+ axitinib helped patientslive longercompared to sunitinib A clinical trial compared patients with advanced renal cell carcinoma who received KEYTRUDA, an immunotherapy, in combination with axitinib, a tyrosine kinase inhibitor (TKI), to thos...
Belzutifan, XmAbA 808, XL092, VB10.NEO, Savolitinib, RC198, NKT2152, NGM707, MEDI5752, ADI-270, ALLO 316, KO 2806, TT-10, Fruquintinib, AB 2100,and others are under different phases of adva...
Brian I. Rini, MD, FASCO, Ingram professor of medicine, Division of Hematology Oncology, chief of Clinical Trials, Vanderbilt-Ingram University Cancer Center, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma (RCC) through the phase 2 OPTIC RCC tri...
Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.
Here, Jaime Merchan, MD, professor, co-leader of the Translational and Clinical Oncology Research Program, and director of the Phase 1 Clinical Trials Program at the Sylvester Comprehensive Cancer Center at the University of Miami, discusses findings from this analysis presented at t...
Radiologic Assessment May Be Used Before First Line Therapy for mccRCC Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney Cancer CBM588 May Improve Clinical Outcomes in Metastatic RCC Abemaciclib May Show Synergistic Effect in Kidney Cancer Combination TrialsRelated...
The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups. A total of 751 patients were enrolled; median age was 69years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (...
The treatment of metastatic kidney cancer is rapidly evolving with the shift from immune checkpoint inhibitor monotherapy to combination therapy. In 2018, the combination of nivolumab–ipilimumab received regulatory approval and multiple positive clinical trials were reported with combinations of PD-1 or ...
Three patients have been receiving Pembrolizumab and prednisone combination therapy for 4 months; no rejection or cancer progression was observed. Upcoming clinical trials with large cohorts will hopefully elucidate the optimal immunotherapy and immunosuppressive regimens to successfully balance ...
" said Choueiri. The CLEAR trial is the last of theclinical trialsthat were launched to compare immunotherapy and targeted drug combinations to sunitinib, and sunitinib will not be the comparison drug in future trials because the combinations have proven superior in these advanced kidney cancer ...